Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

NCT06525246 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IIIB Non-small Cell Lung Cancer
Stage IIIC Non-Small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Cancer
EGFR Mutation-Related Tumors

Interventions

DRUG: ONO-7475
DRUG: Osimertinib Mesylate

Sponsor

Ono Pharmaceutical Co., Ltd.